BioNTech SE ( ($BNTX) ) has shared an update. On April 4, 2025, BioNTech SE announced the invitation to its Annual General Meeting scheduled for ...

From stock decline to Hold rating, explore their growth strategy, client focus, and potential gains. Click for my MRVI update ...

US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...

Mitsubishi UFJ Asset Management Co. Ltd. reduced its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 20.0% in the 4th ...

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 36.1% during the fourth quarter, according to its most recent Form ...

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

We recently published a list of 10 Micro-Cap Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a ...

Vaccine stocks have been under significant pressure in recent days following news that the FDA director who oversaw the ...

The U.S. FDA has missed a key deadline to decide whether to grant full approval to Novavax's (NASDAQ:NVAX) COVID-19 vaccine.

The delay in approval is a setback for Novavax, as the company had anticipated a positive outcome based on the FDA’s initial deadline. The FDA’s decision to require more data before proceeding with ...

Highlights,Revisions in market valuation reflect varying assessments of BioNTech's standing.,Institutional stakeholders adjust their holdings in response to industry trends.,Continued progress in the ...